Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Peter Kent Hawryluk MBA | CEO, President & Director | 571.2k | -- | 1969 |
Mr. Richard B. Bartram CPA | Chief Financial Officer | 578k | -- | 1981 |
Dr. Steven J. Prestrelski M.B.A., MBA, Ph.D. | Chief Scientific Officer | -- | -- | 1964 |
Mr. Matt Gambino | Vice President of Marketing | -- | -- | -- |
Ms. Michelle Graham | Chief Human Resources Officer | -- | -- | 1967 |
Dr. Salomon Azoulay | Chief Medical Officer | -- | -- | 1957 |
MBX Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 38
Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Corporate Governance
Upcoming Events
November 7, 2024 at 1:00 PM UTC
MBX Biosciences, Inc. Earnings Date
Recent Events
August 30, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
August 26, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
August 23, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission